Vaisala’s Q2 was strong with solid volume growth, favorable sales mix in IM and continued OPEX disci...
Redeye was hoping for higher sales in the second quarter.
- Earnings up y-o-y, but still undershot our estimates in Q2 - Profitability issues should be mainly...
We upgrade adjusted EBIT by 2-3% for 2024-26E, encouraged by a continued healthy North American mark...
- Optimism running high after another solid quarter - Positive long-term revisions, '26e EBIT up 1% ...
- 3% organic sales growth y-o-y - Lower profitability than we expected - Adj.
Vaisala’s delivered very strong figures for Q2/24 as our estimates were topped on both net sales and...
Focus has reverted to project and service operations.
- '24e-'25e EBITA down 2-3% - Capacity investments to aid organic growth - '25e lease adj.
- EBIT SEK 30m vs. ABGSCe SEK 63m; Q3e likely better - Pulp prices at ATHs, but may have peaked shor...
Redeye briefly comments on Mendus announcing a collaboration with Institut Bergonié that involves tr...
Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer cen...
Redeye updates on W5 following Q2-results which came in below our expectations.
- Organic growth of 9% vs. cons. 9.5% - Adj. EBITA SEK 141m, 3% below consensus - Gross margin gains...
A tender offer was made for Innofactor’s shares, with the offer price set at EUR 1.
Redeye updates its estimates and valuation following Mentice’s Q2 2024 report.
Redeye retains its positive stance towards Hanza despite a softer Q2 report than expected regarding ...
- Minor positive estimate revisions - Expect primarily volume-driven growth - FVR of SEK 20-35 reite...
- Q2 was likely the trough - Small estimate revisions, good prospects for a better H2 - Poised for i...
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with a more in-de...